genomics in the age of i-o
Published 2 years ago • 153 plays • Length 9:00Download video MP4
Download video MP3
Similar videos
-
0:56
the role of navtemadlin in the mpn treatment landscape
-
0:52
genomic profiling at diagnosis of myeloid neoplasms
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
3:49
factors influencing mpn progression
-
1:44
the genomics of rt and prognostic implications of rt characterization
-
2:06
how the mpn field has evolved over the years: novel agents, trials, and more
-
4:01
the latest genomic updates in the field of mds
-
1:25
the current approach to managing patients with prefibrotic pmf
-
3:35
epigenomics in precision oncology
-
24:30
practical applications for quality improvement in myelofibrosis management: a video brief on less...
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
1:26
current and emerging prognostic factors for mds/mpn
-
5:36
mcl0208: identification of novel genomic prognostic factors
-
2:00
an update on the genomic landscape of mm
-
1:53
classifying mpns with molecular genetic markers
-
1:48
the evolving role of ai in mpns
-
2:11
the management of post-mpn aml
-
2:23
the importance of genomic testing in cll in the era of novel therapies
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis